Complementary Treatments in Thymic Neoplasms: Steroids and Octreotide

  • Liliana Montella
  • Giovannella Palmieri


Permanent control of disease in heavily pretreated patients with metastatic thymic tumors can be difficult to obtain [1]. Alternative treatment strategies have been tested. Following, we will focus on the basic knowledge supporting clinical treatment with steroids and/or somatostatin analogs in thymic epithelial tumors (TET).


Glucocorticoid Receptor Thymic Carcinoma Thymic Epithelial Cell Thymic Tumor Thymic Epithelial Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thomas CR, Wright CD, Loehrer PJ (1999) Thymoma: State of the art. J Clin Oncol 17:2280–2289PubMedGoogle Scholar
  2. 2.
    Müller-Hermelink HK, Marx A (1999) Pathological aspects of malignant and benign thymic disorders. Ann Med 31(Suppl 2):5–14PubMedGoogle Scholar
  3. 3.
    Rosai J, Sobin LH (1999) Histological typing of tumors of the thymus. In: Word Health Organization, International Histological Classification of Tumors, Germany, Heidelberg, pp 1–65Google Scholar
  4. 4.
    Almog C, Pik A, Weisberg D, Herczeg E (1978) Regression of malignant thymoma with metastases after treatment with adrenocortical steroids. Isr J Med Sci 14:476–480PubMedGoogle Scholar
  5. 5.
    Mizuno T, Hashimoto T, Yamakawa Y et al (1992) A case of small thymoma associated with myasthenia gravis in which the tumor was reduced by corticosteroid therapy. Nippon Kyobu Geha Gakkai Zasshi 40:975–977Google Scholar
  6. 6.
    Fujiwara T, Mizobuchi T, Shibuya K et al (2007) Rapid regression of stage IVb invasive thymoma under palliative corticosteroid administration. Gen Thorac Cardiovasc Surg 55:180–183PubMedCrossRefGoogle Scholar
  7. 7.
    Barratt S, Puthucheary ZA, Plummeridge M (2007) Complete regression of a thymoma to glucocorticoids, commenced for palliation of symptoms. Eur J Cardiothorac Surg 31:1142–1143PubMedCrossRefGoogle Scholar
  8. 8.
    Hu E, Levine J (1986) Chemotherapy of malignant thymoma. Case report and review of the literature. Cancer 57:1101–1104PubMedCrossRefGoogle Scholar
  9. 9.
    Suda T, Sugimura S, Hattori Y et al (1998) High-dose methylprednisolone-containing chemotherapy in advanced invasive thymoma-report of three cases. Nippon Kyobu Geha Gakkai Zasshi 46:115–120Google Scholar
  10. 10.
    Dardenne M, Itoh T, Homo-Delarche F (1986) Presence of glucocorticoid receptors in cultured thymic epithelial cells. Cell Immunol 100:112PubMedCrossRefGoogle Scholar
  11. 11.
    Dardenne M, Savino W (1990) Neuroendocrine control of the thymic epithelium: Modulation of thymic endocrine function, cytokeratin expression and cell proliferation by hormones and neuropeptides. Progr Neuro Endocrin Immunol 3:18–25Google Scholar
  12. 12.
    Funakoshi Y, Shiono H, Inoue M et al (2005) Glucocorticoids induce G1 cell cycle arrest in human neo-plastic thymic epithelial cells. J Cancer Res Clin Oncol 131:314–322PubMedCrossRefGoogle Scholar
  13. 13.
    Tandan R, Taylor R, Di Costanzo DP et al (1990) Metastasizing thymoma and myasthenia gravis. Favorable response to glucocorticoids after failed chemotherapy and radiation therapy. Cancer 65:1286–1290PubMedCrossRefGoogle Scholar
  14. 4.
    Kirkove C, Berghmans J, Noel H, van de Merckt J (1992) Dramatic response of recurrent invasive thymoma to high doses of corticosteroids. Clin Oncol (R Coll Radiol) 4:64–66Google Scholar
  15. 15.
    Hayashi M, Taira M, Yamawaki I, Ohkawa S (2006) High-dose methylprednisolone with chemotherapy for invasive thymoma: A case report. Anticancer Res 26(5B):3645–3648PubMedGoogle Scholar
  16. 16.
    Yokoi K, Matsuguma H, Nakahara R et al (2007) Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2:73–78PubMedCrossRefGoogle Scholar
  17. 17.
    Kobayashi Y, Fujii Y, Yano M et al (2006) Preoperative steroid pulse therapy for invasive thymoma: Clinical experience and mechanism of action. Cancer 106:1901–1907PubMedCrossRefGoogle Scholar
  18. 18.
    Tiseo M, Monetti F, Ferrarini M et al (2005) CASE 1. Complete remission to corticosteroids in an octreotiderefractory thymoma. J Clin Oncol 23:1578–1579PubMedCrossRefGoogle Scholar
  19. 19.
    Green JD, Forman WH (1974) Response of thymoma to steroids. Chest 65:114–116PubMedCrossRefGoogle Scholar
  20. 20.
    Palmieri G, Lastoria S, Colao A et al (1997) Successful treatment of a patient with a thymoma and pure-red cell aplasia with octreotide and prednisone. N Engl J Med 336:263–265PubMedCrossRefGoogle Scholar
  21. 21.
    Krulich L, Dhariwal APS, McCann SM (1968) Stimulatory and inhibitory effect of purified extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783–790PubMedCrossRefGoogle Scholar
  22. 22.
    Schonbrunn A (1999) Somatostatin receptors present knowledge and future directions. Ann Oncol 10(Suppl 2):17–21CrossRefGoogle Scholar
  23. 23.
    Eriksson B, Oberg K (1999) Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook. Ann Oncol 10(Suppl 2):S31–S38PubMedCrossRefGoogle Scholar
  24. 24.
    Schultz S, Schultz S, Schmitt J et al (1998) Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 4:2047–2052Google Scholar
  25. 25.
    Nilsson S, Reubi JC, Kalkner KM et al (1995) Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res 55:5805s–5810sPubMedGoogle Scholar
  26. 26.
    Reubi JC, Waser B, van Hagen PM et al (1992) In vivo and in vitro detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 50:895–900PubMedCrossRefGoogle Scholar
  27. 27.
    van Hagen PM, Hofland LJ, ten Bokum AMC et al (1999) Neuropeptides and their receptors in the immune system. Ann Med 31(Suppl 2):15–22PubMedGoogle Scholar
  28. 28.
    Guillermet-Guilbert J, Lahlou H, Cordelier P et al (2005) Physiology of somatostatin receptors. J Endocrinol Invest 28(Suppl 11):5–9Google Scholar
  29. 29.
    Adams RL, Adams IP, Lindow SW et al (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493–1498PubMedCrossRefGoogle Scholar
  30. 30.
    Ferone D, van Hagen PM, Colao A et al (1999) Somatostatin receptors in the thymus. Ann Med 31(Suppl 2):28–33PubMedGoogle Scholar
  31. 31.
    Dardenne M (1999) Role of thymic peptides as transmitters between the neuroendocrine and immune system. Ann Med 31(Suppl 2):34–39PubMedGoogle Scholar
  32. 32.
    Hofland LJ, van Hagen PM, Lamberts SWJ (1999) Functional role of somatostatin receptors in neuroendo crine and immune cells. Ann Med 31(Suppl 2):23–27PubMedGoogle Scholar
  33. 33.
    Fuller PJ, Verity K (1989) Somatostatin gene expression in the thymus gland. J Immunol 143:1015–1017PubMedGoogle Scholar
  34. 34.
    Savino W, Arzt E, Dardenne M (1999) Immuno-neuroendocrine connectivity: The paradigm of the thymus-hypothalamus/pituitary axis. Neuroimmuno-modulation 6:126–136CrossRefGoogle Scholar
  35. 35.
    Reubi JC, Waser B, Horisberger U et al (1993) In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 82:2143–2151PubMedGoogle Scholar
  36. 36.
    Reubi JC, Horisberger U, Kappeler A et al (1998) Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood 92:191–197PubMedGoogle Scholar
  37. 37.
    Ferone D, van Hagen PM, van Koetsveld PM et al (1999) In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 140:373–380PubMedCrossRefGoogle Scholar
  38. 38.
    Timsit J, Savino W, Safieh B et al (1992) Growth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells. J Clin Endocrinol Metab 75:183–188PubMedCrossRefGoogle Scholar
  39. 39.
    Ferone D, van Hagen PM, Kweekkeboom DJ et al (2000) Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 85:1719–1726PubMedCrossRefGoogle Scholar
  40. 40.
    Ferone D, Kwekkeboom DJ, Pivonello R et al (2001) In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. J Endocrinol Invest 24:522–528PubMedGoogle Scholar
  41. 41.
    Lastoria S, Palmieri G, Ferone D et al (2001) In vitro and in vivo detection of somatostatin receptors in thymic tumors. 9th European Congress of Endocrinology, TorinoGoogle Scholar
  42. 42.
    Lauriola L, Erlandson RA, Rosai J (1998) Neuroendocrine differentiation is a common feature of thymic carcinoma. Am J Surg Pathol 22:1059–1066PubMedCrossRefGoogle Scholar
  43. 43.
    Hishima T, Fukayama M, Hayashi Y et al (1998) Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma. Hum Pathol 29:330–338PubMedCrossRefGoogle Scholar
  44. 44.
    Lastoria S, Vergara E, Palmieri G et al (1998) In vivo detection of malignant thymic masses by Indium-111-DTPA-d-Phe1-octreotide scintigraphy. J Nucl Med 39:634–639PubMedGoogle Scholar
  45. 45.
    Lastoria S, Palmieri G, Muto P, Lombardi G (1999) Functional imaging of thymic disorders. Ann Med 31(Suppl 2):63–69PubMedGoogle Scholar
  46. 46.
    Palmieri G, Montella L, Martignetti A et al (2002) Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 94:1414–1420PubMedCrossRefGoogle Scholar
  47. 47.
    Loehrer PJ, Wang W, Johnson DH, Ettinger DS (2004) Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial. J Clin Oncol 22:293–299PubMedCrossRefGoogle Scholar
  48. 48.
    Masci AM, Palmieri G, Vitiello L et al (2003) Clonal expansion of CD8+ BV8 T lymphocytes in bone marrow characterizes thymoma-associated B-lymphopenia. Blood 101:3106–3108PubMedCrossRefGoogle Scholar
  49. 49.
    Montella L, Masci A, Merkabaoui G et al (2003) B-cell lymphopenia and hypogammaglobulinemia in thymoma patients. Ann Hematol 82:343–347PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  • Liliana Montella
    • 1
  • Giovannella Palmieri
    • 2
  1. 1.Medical Oncology Unit“San Giovanni di Dio” HospitalNaplesItaly
  2. 2.Molecular and Clinical Endocrinology and Oncology DepartmentUniversity “Federico II”NaplesItaly

Personalised recommendations